Olink

Olink®
Part of Thermo Fisher Scientific

Immune evasive DNA donors and recombinases license kilobase-scale writing

Nature, 2026

Tou C., Xie K., Ferreira da Silva J., Kalailingam P., Amar-Lewis E., Rufino-Ramos D., Sawyer W., Eller M., Starzyk J., Majumdar I., Wang J., Lee D., Yang S., Meis R., Dahl G., Li J., Shan R., Artzi N., Musolino P., Wu H., Kleinstiver B.

Disease areaApplication areaSample typeProducts
Technical Studies
Technical Evaluation
Mouse Plasma
O

Olink Target 48 Mouse

Abstract

Genome-editing technologies that use recombinases to insert kilobase-scale DNA sequences into mammalian genomes canonically require large double-stranded DNA (dsDNA) donors1,2. However, dsDNA molecules evoke problematic and toxic innate immune responses, limiting integration efficiencies and generally constraining applicability to ex vivo or immune-deficient contexts. By harnessing mechanisms of integrative prokaryotic viruses and mobile genetic elements, here we demonstrate that recombinases are compatible with immune evasive circular single-stranded DNA molecules optimally bearing a partial-duplex region that reconstitutes the recombinase recognition sequence. This approach, which we term integration through nucleus-synthesized template addition of large lengths (INSTALL), is compatible with diverse protein and RNA-guided recombinases for high-fidelity kilobase-scale human genome writing. INSTALL minimizes innate immune responses in primary human cells and in mice, improving recombinase-mediated integration efficiencies and supporting systemic in vivo non-viral DNA delivery by substantially increasing tolerability and broadening the dosing range compared with lipid nanoparticle-delivered dsDNA molecules. Together, INSTALL overcomes fundamental challenges for DNA delivery and integration methods by synergizing immune-stealth nucleic acids with recombinases to enable kilobase-scale integration strategies without viral vectors.

Read publication ↗